Sawai Soars To New Heights In US But Flounders In Domestic Market
One-Off Expenses, NHI Revision And Shipment Limitations All Hurt Japanese Firm
While Sawai’s dominant Japanese business appeared under some strain as the firm started its 2022 financial year, the company appears confident that it is still on track to meet its annual forecast.
You may also be interested in...
Sawai’s Upsher-Smith business in the US has announced a pair of deals that will see the firm expand an existing partnership with Appco for a “near-term generic product opportunity” as well as divesting two “dormant” ANDAs in favor of a focus on more immediate assets.
Dr Reddy’s is the first of six generics firms to challenge Intercept’s Ocaliva patents to reach a settlement, and will be able to market its product in the US from 2035 onward.
Kobayashi Kako has agreed to transfer ownership of eight of its production, research and distribution facilities to Sawai, which will use them to expand the manufacturing of its own generics. Business was suspended at Kobayashi Kako for 116 days this year after the company’s manufacturing deficiencies were linked to two deaths.